Biotech
Wednesday, October 30th, 2024 3:46 pm EDT
Key Points
- Strong Q3 Performance and Raised Profit Guidance: Biogen exceeded revenue and adjusted earnings expectations for the third quarter, driven by the growing success of its new Alzheimer’s drug Leqembi and other recent products. This led the company to raise its full-year profit guidance to $16.10–$16.60 per share.
- Increased Sales of Alzheimer’s Drug Leqembi: Sales of Leqembi reached $67 million for the quarter, surpassing Wall Street estimates of $50 million and significantly growing from $10 million last year. The drug’s adoption has been gradual due to diagnostic and access bottlenecks but is gaining momentum.
- Offsetting Multiple Sclerosis Revenue Decline: Leqembi, along with new treatments for rare diseases and depression, helped counter a 3% year-over-year decline in Biogen’s multiple sclerosis drug revenue, maintaining overall quarterly sales at $2.47 billion.
Biogen on Wednesday reported third-quarter revenue and adjusted earnings that topped expectations while raising its full-year profit guidance, as sales of its breakthrough Alzheimer’s drug, Leqembi, and other new products gain traction.
Biogen now expects full-year adjusted earnings to come in between $16.10 and $16.60 per share, up from a previous forecast of $15.75 to $16.25 per share. The biotech company still anticipates 2024 sales to decline by a low-single-digit percentage.
Leqembi, which Biogen shares with the Japanese drugmaker Eisai, became the second drug proven to slow the progression of Alzheimer’s to win approval in the U.S. last summer. The therapy’s launch has been gradual due to bottlenecks related to diagnostic test requirements, regular brain scans and finding neurologists, among other issues.
More CNBC health coverage
- FTC sues drug middlemen for allegedly inflating insulin prices
- Pfizer says drug for deadly cancer condition that causes weight loss shows positive trial data
- Gilead says its twice-yearly shot cut HIV infections by 96% in trial
Still, uptake of Leqembi has been increasing over the last few quarters. The treatment brought in $67 million in sales for the third quarter, including $39 million from the U.S.
Wall Street analysts had expected global sales of $50 million for Leqembi, according to estimates compiled by StreetAccount. The drug posted just $10 million in sales last year following its launch.
It is unclear how many patients are currently taking the drug. Leqembi, along with Biogen’s new rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company’s multiple sclerosis products.
Here’s what Biogen reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
- Earnings per share: $4.08 adjusted vs. $3.79 expected
- Revenue: $2.47 billion vs. $2.43 billion expected
Biogen booked sales of $2.47 billion for the quarter, which is down around 3% from the year-earlier period.
The drugmaker posted net income of $388.5 million, or $2.66 per share, for the period ended Sept. 30. That compares with a net loss of $68.1 million, or 47 cents per share, for the same period a year ago.
Adjusting for one-time items, including certain restructuring charges and costs associated with intangible assets, the company reported earnings of $4.08 per share.
For the full original article on CNBC, please click here: https://www.cnbc.com/2024/10/30/biogen-biib-earnings-q3-2024.html
